Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Philippines FDA Slashes Generic Approval Timelines
Cuts Review From 120 To 45 Days As President Urges Lower Prices ‘Similar To India’
Feb 14 2024
•
By
David Wallace
The FDA in the Philippines is cutting generic approval timelines • Source: Shutterstock
More from Regulation
More from Policy & Regulation